***Background.*** Streptococci are a known cause of complicated skin and soft tissue infections (cSSTI). Dalbavancin, a lipoglycopeptide antibiotic has been studied in 3 global phase 3 randomized, double-blind, controlled trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and cSSTI. The objective of this analysis is to evaluate outcomes for patients with streptococcal skin infections enrolled in the 3 global trials.

***Methods.*** Patients enrolled in the 3 phase 3 ABSSSI/cSSTI trials with baseline cultures positive for streptococcal species were identified. In these trials, dalbavancin, 1 g IV on day 1 followed by 500mg IV on day 8 was compared to either IV vancomycin or IV linezolid with an option to switch to oral linezolid. The MIC distribution of streptococcal isolates and clinical outcomes for patients with streptococcal skin infections were determined.

***Results.*** The *in vitro* MIC~90~ to dalbavancin for each strain of streptococci was ≤0.06 mcg/mL.

###### 

Distribution of streptococci in 3 phase 3 ABSSSI/cSSTI trials

                                    DUR001-301/302 + VER001-9                
  --------------------------------- --------------------------- ------- ---- -----
  **Baseline Isolates**             N=695                       N=521        
  *S. pyogenes*                     50                          7.2     46   8.8
  *S. agalactiae*                   24                          3.5     22   4.2
  Streptococcus viridans group      17                          2.4     10   1.9
  *S. dysgalactiae*                 8                           1.2     2    0.4
  Streptococcus Group C             5                           0.7     5    1.0
  Streptococcus Group G             10                          1.4     7    1.3
  *Streptococcus anginosus* Group   22                          3.2     25   4.8
  *S. anginosus*                    6                           0.9     4    0.8
  *S. constellatus*                 15                          2.2     16   3.1
  *S. intermedius*                  6                           0.9     7    1.3
  *Streptococcus pneumoniae*        1                           0.1     0    0.0
  Other streptococci\*              2                           0.3     5    1.0

includes S. bovis, S. gordonii, S. mitis, S. mutans, S. salivarius and other streptococcal species

###### 

Clinical Success\* at EOT by Key Target Pathogen

  Baseline Pathogen   Dalbavancin n/N (%)   Comparator n/N (%)
  ------------------- --------------------- --------------------
  *S. pyogenes*       43/45 (95.6)          37/39 (94.9)
  *S. agalactiae*     19/21 (90.5)          12/14 (85.7)
  *S. dysgalactiae*   8/8 (100)             2/2 (100)
  *S. anginosus*      6/6 (100)             3/3 (100)
  *S. constellatus*   11/11 (100)           14/14 (100)
  *S. intermedius*    4/4 (100)             5/5 (100)

assessed by investigators; EOT = end of treatment

***Conclusion.*** Data from the clinical trial program confirm the *in vitro* activity of dalbavancin against strains of streptococci. Patients with streptococcal skin infections treated with dalbavancin had similar clinical success rates at EOT as those treated with the comparator regimens.
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